A K Pröbstel,
K Dornmair,
R Bittner,
P Sperl,
D Jenne,
S Magalhaes,
A Villalobos,
C Breithaupt,
R Weissert,
U Jacob, [......], T Olsson,
F Brilot,
E Tantsis,
R C Dale,
H Wekerle,
R Hohlfeld,
B Banwell,
A Bar-Or,
E Meinl,
T Derfuss
[show abstract]
[hide abstract]
ABSTRACT: To study the longitudinal dynamics of anti-myelin oligodendrocyte glycoprotein (MOG) autoantibodies in childhood demyelinating diseases.
We addressed the kinetics of anti-MOG immunoglobulins in a prospective study comprising 77 pediatric patients. This was supplemented by a cross-sectional study analyzing 126 pediatric patients with acute demyelination and 62 adult patients with multiple sclerosis (MS). MOG-transfected cells were used for detection of antibodies by flow cytometry.
Twenty-five children who were anti-MOG immunoglobulin (Ig) positive at disease onset were followed for up to 5 years. Anti-MOG antibodies rapidly and continuously declined in all 16 monophasic patients with acute disseminated encephalomyelitis and in one patient with clinically isolated syndrome. In contrast, in 6 of 8 patients (75%) eventually diagnosed with childhood MS, the antibodies to MOG persisted with fluctuations showing a second increase during an observation period of up to 5 years. Antibodies to MOG were mainly IgG 1 and their binding was largely blocked by pathogenic anti-MOG antibodies derived from a spontaneous animal model of autoimmune encephalitis. The cross-sectional part of our study elaborated that anti-MOG Ig was present in about 25% of children with acute demyelination, but in none of the pediatric or adult controls. Sera from 4/62 (6%) adult patients with MS had anti-MOG IgG at low levels.
The persistence or disappearance of antibodies to MOG may have prognostic relevance for acute childhood demyelination.
Neurology 08/2011; 77(6):580-8. · 8.31 Impact Factor
